Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | YMAB |
---|---|---|
09:32 ET | 1488 | 12.73 |
09:39 ET | 1143 | 12.5548 |
09:41 ET | 400 | 12.71 |
09:43 ET | 9503 | 12.88 |
09:45 ET | 1752 | 12.845 |
09:50 ET | 100 | 12.83 |
09:52 ET | 100 | 12.83 |
09:54 ET | 200 | 12.82 |
09:56 ET | 100 | 12.79 |
09:57 ET | 300 | 12.735 |
10:01 ET | 100 | 12.65 |
10:03 ET | 1134 | 12.56 |
10:06 ET | 100 | 12.6 |
10:10 ET | 100 | 12.55 |
10:24 ET | 100 | 12.44 |
10:30 ET | 300 | 12.405 |
10:33 ET | 100 | 12.35 |
10:35 ET | 522 | 12.33 |
10:37 ET | 1500 | 12.46 |
10:42 ET | 470 | 12.395 |
10:46 ET | 100 | 12.41 |
10:48 ET | 816 | 12.405 |
10:50 ET | 200 | 12.43 |
11:02 ET | 300 | 12.42 |
11:06 ET | 100 | 12.42 |
11:08 ET | 100 | 12.425 |
11:09 ET | 100 | 12.43 |
11:18 ET | 200 | 12.435 |
11:20 ET | 1189 | 12.36 |
11:24 ET | 200 | 12.33 |
11:31 ET | 300 | 12.31 |
11:33 ET | 100 | 12.3 |
11:38 ET | 100 | 12.325 |
11:42 ET | 100 | 12.3 |
11:49 ET | 300 | 12.29 |
11:51 ET | 900 | 12.34 |
11:56 ET | 138 | 12.33 |
12:00 ET | 200 | 12.33 |
12:05 ET | 100 | 12.29 |
12:07 ET | 610 | 12.275 |
12:09 ET | 200 | 12.28 |
12:12 ET | 100 | 12.28 |
12:14 ET | 200 | 12.285 |
12:16 ET | 1000 | 12.265 |
12:18 ET | 200 | 12.255 |
12:20 ET | 344 | 12.28 |
12:23 ET | 100 | 12.26 |
12:27 ET | 235 | 12.26 |
12:30 ET | 200 | 12.26 |
12:32 ET | 100 | 12.285 |
12:34 ET | 404 | 12.27 |
12:36 ET | 400 | 12.28 |
12:38 ET | 256003 | 12.325 |
12:39 ET | 200 | 12.325 |
12:41 ET | 1216 | 12.41 |
12:43 ET | 166 | 12.405 |
12:45 ET | 300 | 12.39 |
12:48 ET | 2335 | 12.39 |
12:50 ET | 1829 | 12.23 |
12:52 ET | 1200 | 12.19 |
12:54 ET | 616 | 12.14 |
01:01 ET | 1099 | 12.14 |
01:03 ET | 100 | 12.2 |
01:08 ET | 100 | 12.185 |
01:14 ET | 400 | 12.19 |
01:15 ET | 733 | 12.19 |
01:17 ET | 976 | 12.225 |
01:19 ET | 200 | 12.25 |
01:21 ET | 113 | 12.24 |
01:26 ET | 200 | 12.3 |
01:32 ET | 100 | 12.26 |
01:33 ET | 100 | 12.26 |
01:39 ET | 700 | 12.305 |
01:46 ET | 400 | 12.26 |
01:50 ET | 250 | 12.24 |
02:00 ET | 287 | 12.22 |
02:02 ET | 100 | 12.22 |
02:04 ET | 100 | 12.2 |
02:06 ET | 100 | 12.2 |
02:13 ET | 100 | 12.19 |
02:22 ET | 100 | 12.18 |
02:24 ET | 132 | 12.19 |
02:27 ET | 700 | 12.17 |
02:29 ET | 100 | 12.165 |
02:31 ET | 300 | 12.13 |
02:33 ET | 1689 | 12.22 |
02:36 ET | 1307 | 12.245 |
02:42 ET | 736 | 12.245 |
02:44 ET | 300 | 12.26 |
02:45 ET | 200 | 12.25 |
02:51 ET | 224 | 12.25 |
02:54 ET | 478 | 12.295 |
02:56 ET | 100 | 12.295 |
02:58 ET | 200 | 12.25 |
03:00 ET | 600 | 12.245 |
03:02 ET | 500 | 12.25 |
03:05 ET | 1482 | 12.29 |
03:14 ET | 198 | 12.3 |
03:20 ET | 193 | 12.3001 |
03:21 ET | 300 | 12.315 |
03:25 ET | 700 | 12.34 |
03:32 ET | 355 | 12.32 |
03:38 ET | 100 | 12.31 |
03:39 ET | 300 | 12.33 |
03:45 ET | 1529 | 12.3 |
03:48 ET | 200 | 12.31 |
03:50 ET | 900 | 12.325 |
03:52 ET | 487 | 12.3 |
03:54 ET | 780 | 12.26 |
03:56 ET | 2773 | 12.28 |
03:57 ET | 1166 | 12.26 |
03:59 ET | 19480 | 12.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Y-mAbs Therapeutics Inc | 531.0M | -24.8x | --- |
Urogen Pharma Ltd | 480.5M | -3.9x | --- |
Zymeworks Inc | 599.6M | -5.1x | --- |
Alector Inc | 474.2M | -3.1x | --- |
Editas Medicine Inc | 427.6M | -2.6x | --- |
SAGE Therapeutics Inc | 668.6M | -1.3x | --- |
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $531.0M |
---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 43.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-0.50 |
Book Value | $2.31 |
P/E Ratio | -24.8x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.